Literature DB >> 21648283

Neonatal screening for congenital adrenal hyperplasia: transitory elevation of 17-hydroxyprogesterone.

Belén Huidobro Fernández1, Maite Echeverria Fernández, Elena Dulin Iñiguez, Begoña Ezquieta Zubicaray, Maria Belén Roldán Martín, Maria Dolores Rodríguez Arnao, Amparo Rodríguez Sánchez.   

Abstract

AIM: The aim of the study was to identify patients with transitory elevation (TE) of 17-hydroxyprogesterone (17-OHP) using neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD) and to compare them with patients with 21-OHD.
METHODS: This was a retrospective study of patients with high 17-OHP levels detected during newborn screening in Madrid, Spain.
RESULTS: 17-OHP levels were significantly higher in the 33 21-OHD patients, who tended to present hyponatraemia and hyperkalemia. The TE-17-OHP group was characterized by normal initial physical examination (88.8% vs. 39.4%), lower gestational age and a higher number of stressful perinatal factors. 17-OHP levels decreased spontaneously in this group. Molecular diagnosis allowed us to discard the most frequent mutations associated with 21-OHD.
CONCLUSIONS: Newborns with slightly increased 17-OHP levels and normal results for physical examination, acid-base equilibrium, glycemia, electrolytes and perinatal stress factors should be carefully evaluated. Decisions on treatment should be postponed until these results are available.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21648283

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  1 in total

1.  Newborn screening for congenital adrenal hyperplasia in New York State.

Authors:  Melissa Pearce; Lenore DeMartino; Rebecca McMahon; Rhonda Hamel; Breanne Maloney; Daniele-Marisa Stansfield; Emily C McGrath; Amanda Occhionero; Adam Gearhart; Michele Caggana; Norma P Tavakoli
Journal:  Mol Genet Metab Rep       Date:  2016-03-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.